EUVIMEDEUVIMED entdecken
Multizentrische StudieLeserbrief

Neoadjuvant Treatment of Locally Advanced Thyroid Cancer: A Preliminary Latin American Experience

Fabián Pitoia iD, Erika Abelleira, Alejandro Román-González, Debora L S Danilovic iD, Rafael Selbach Scheffel, Ana Luiza Maia, Ana O Hoff, Inés Califano iD

Thyroid® · 2024

DOI: 10.1089/thy.2024.0090 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Thyroid®, 2024. Verfasst von Fabián Pitoia und 7 weiteren Autor:innen. Beteiligte Einrichtung: Hospital de Clínicas "José de San Martín" University of Buenos Aires, Buenos Aires, Argentina. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Neoadjuvant Therapy. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 10 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Surgical resection is not always achievable in thyroid cancer patients. Neoadjuvant therapy is rarely used, but recent trends favor multikinase inhibitors or selective tyrosine kinase inhibitors. These aim to reduce tumor volume, enabling previously unfeasible surgeries. Patients and Methods: Consecutive patients with locally advanced malignant thyroid tumors who received systemic therapies with a neoadjuvant intention were included in this retrospective multicenter case series conducted in five Latin American referral centers. Primary outcomes were pre- versus postneoadjuvant response evaluations using the Response Evaluation Criteria in Solid Tumors, feasibility of surgery, and completeness of resection. Secondary outcomes were mortality and status at the last visit.

Results

Twenty-seven patients were included in this analysis. Patients with unresectable differentiated thyroid cancer (DTC) or poorly differentiated thyroid cancer (PDTC) received sorafenib ( n = 6) or lenvatinib ( n = 12), those with medullary thyroid cancer (MTC) were treated with vandetanib ( n = 5) or selpercatinib ( n = 1), and those with anaplastic thyroid cancer (ATC) harboring a BRAF V600E mutation ( n = 3) received dabrafenib and trametinib. The median patient age was 66 years (range 12–82), and 52% of the patients were female. In patients with PTC and PDTC, the median reduction in the diameter of the primary tumor was 25% (range 0–100%) after a median of 6 months of treatment. Surgical intervention was performed in 10 (55%) of the patients. Among these, six patients (60%) achieved R0/R1 resection status. Six patients with MTC had a median reduction in tumor diameter of 24.5% (range 1–49) after a median treatment time of 9.5 months. Only one patient receiving selpercatinib, with a tumoral reduction of 25% could undergo surgery, resulting in an R2 resection due to extensive mediastinal extension. Three patients with ATC showed a median tumor diameter reduction of 42% (range 6.7–50) after a median treatment time of 2 months. Two patients underwent surgical intervention and achieved R1 and R2 resection, respectively.

Conclusions

While neoadjuvant therapy achieved tumoral responses, surgical resection was feasible in 55% of DTC, 33% of ATC, and 16% of MTC patients, with R0/R1 resection in 26% of the cohort, underscoring the need for patient selection and further research in this area.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid NeoplasmsNeoadjuvant TherapyHumansFemaleMaleMiddle AgedAgedRetrospective StudiesAdultAged, 80 and overYoung AdultAdolescentChildThyroidectomyLatin AmericaTreatment OutcomeProtein Kinase InhibitorsPhenylurea CompoundsCarcinoma, NeuroendocrineQuinolines

Stichwörter der Autor:innen

locally advanced thyroid cancerneoadjuvant therapyreal-life

Substanzen

Protein Kinase InhibitorsPhenylurea CompoundslenvatinibQuinolines

Autor:innen und Institutionen

  • Hospital de Clínicas "José de San Martín" University of Buenos Aires, Buenos Aires, Argentina.
  • Hospital San Vicente Fundación-Universidad de Antioquia, Medellín, Colombia.
  • Laboratorio de Endocrinologia Celular e Molecular (LIM25), Hospital das Clinicas HCFMUSP, Instituto do Cancer do Estado de Sao Paulo, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, Brazil.
  • Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
  • Instituto do Cancer do Estado de Sao Paulo, Universidade de Sao Paulo, São Paulo, Brazil.
  • Instituto de Oncología "Angel H. Roffo" University of Buenos Aires, Buenos Aires, Argentina.

ORCID-Profile: Fabián Pitoia, Debora L S Danilovic, Inés Califano

Zitieren

APA

Pitoia, F., Abelleira, E., Román-González, A., Danilovic, D. L. S., Scheffel, R. S., Maia, A. L., Hoff, A. O., & Califano, I. (2024). Neoadjuvant Treatment of Locally Advanced Thyroid Cancer: A Preliminary Latin American Experience. Thyroid®. https://doi.org/10.1089/thy.2024.0090

Vancouver

Pitoia F, Abelleira E, Román-González A, Danilovic DLS, Scheffel RS, Maia AL, et al. Neoadjuvant Treatment of Locally Advanced Thyroid Cancer: A Preliminary Latin American Experience. Thyroid®. 2024. doi:10.1089/thy.2024.0090

BibTeX
@article{Pitoia2024,
  author = {Pitoia, Fabián and Abelleira, Erika and Román-González, Alejandro and Danilovic, Debora L S and Scheffel, Rafael Selbach and Maia, Ana Luiza and Hoff, Ana O and Califano, Inés},
  title = {Neoadjuvant Treatment of Locally Advanced Thyroid Cancer: A Preliminary Latin American Experience},
  journal = {Thyroid®},
  year = {2024},
  doi = {10.1089/thy.2024.0090}
}
Kostenlos starten →